Use of Antiangiogenic Therapies in Pediatric Solid Tumors
Cancer is an important cause of death in childhood. In recent years, scientists have made an important effort to achieve greater precision and more personalized treatments against cancer. But since only a few pediatric patients have identifiable therapeutic targets, other ways to stop the neoplastic...
Main Authors: | Claudia Ollauri-Ibáñez, Itziar Astigarraga |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/2/253 |
Similar Items
-
Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance
by: Bahare Zarrin, et al.
Published: (2017-01-01) -
Halogenated Flavonoid Derivatives Display Antiangiogenic Activity
by: Mai Khater, et al.
Published: (2022-07-01) -
Safety of Anti-Angiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-Analysis
by: Andrea Spini, et al.
Published: (2022-10-01) -
Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine
by: Hashem O. Alsaab, et al.
Published: (2021-02-01) -
Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
by: Alicia González, et al.
Published: (2021-06-01)